Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Petra Pharma Licenses Takeda’s Serabelisib | Contract Pharma

What are you searching for?

Sign in
Breaking News

Petra Pharma Licenses Takeda’s Serabelisib

Researching new approaches that have the potential to increase tumor responses with PI3K inhibitors and minimize side effects

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Petra Pharma Corporation has secured a global license from Takeda Pharmaceutical Co. to develop, manufacture and commercialize serabelisib and two additional PI3Kα-specific inhibitors. Petra has a license for all human therapeutic uses, except for a subset of undisclosed rare-disease indications, which Takeda had previously out-licensed.  

Petra plans to initiate a Phase 1b/2 study with serabelisib in late 2019 to advance research and insights in PI signaling pathways with a focus on PIK3CA-mutated solid tumors. The PI3K signaling pathway is a frequently mutated pathway in human cancer.

“Today marks a transformational moment for Petra and a new era in the therapeutic use of PI3K inhibitors. We are pioneering new approaches that have the potential to increase tumor responses with PI3K inhibitors and minimize side effects, with profound clinical implications for patients diagnosed with a PIK3CA-mutated tumor,” said president and chief executive officer, Brian O’Callaghan.

This is the first licensing agreement between Petra and Takeda. Financial terms were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics